You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2026

AbstractFullPdf
Feb 2022938969243
Mar 2022952989416
Apr 2022540558220
May 2022526550205
Jun 2022463477175
Jul 2022419432144
Aug 2022879905229
Sep 2022492499146
Oct 2022523531156
Nov 2022487492121
Dec 2022308314104
Jan 2023472478118
Feb 2023388395114
Mar 2023383401166
Apr 2023296305102
May 2023354357121
Jun 2023497505129
Jul 2023317317101
Aug 202347748088
Sep 202325526071
Oct 202328529783
Nov 202331832186
Dec 202325025369
Jan 202415515671
Feb 202426726770
Mar 2024332333143
Apr 202428228699
May 2024308314110
Jun 2024272272127
Jul 202433033386
Aug 202418418557
Sep 2024207213201
Oct 202425425482
Nov 202419519855
Dec 202420120284
Jan 202525725866
Feb 202522322360
Mar 202523523577
Apr 202520320777
May 202517617671
Jun 202511311355
Jul 2025110
Nov 2025221
Mar 2026110
Total15017153144999